Phaseline

Targets › AKR1B1

AKR1B1 (Aldo-keto reductase family 1 member B1): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 3; Neurology, Metabolic and endocrine; next expected readout Dec 2026.

Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols. Displays enzymatic activity towards endogenous metabolites such as aromatic and aliphatic aldehydes, ketones, monosaccharides, bile acids and xenobiotics substrates. (UniProt, P15121)

Open in Phaseline: the race on AKR1B1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Applied TherapeuticsCaficrestat (AT-001)
Aldose reductase inhibitor
AKR1B1Phase 3Diabetic Cardiomyopathies–
Arctic TherapeuticsCaficrestat (NPI-001)
Aldose reductase inhibitor
AKR1B1Phase 2Hereditary Cystatin C Amyloid Angiopathy (HCCAA)Dec 2026
St. John's Research InstituteEpalrestat
Aldose reductase inhibitor
AKR1B1Phase 2Diabetic Neuropathy Peripheral–

Conditions

Hereditary Cystatin C Amyloid Angiopathy (HCCAA) (1) Diabetic Neuropathy Peripheral (1) Diabetic Cardiomyopathies (1)

Modalities

small molecule (3)

Companies

Arctic Therapeutics (1) St. John's Research Institute (1) Applied Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.